{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:43:46Z","timestamp":1792727026954,"version":"4.5.0"},"reference-count":75,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T00:00:00Z","timestamp":1293753600000},"content-version":"vor","delay-in-days":1825,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Nordic countries have the highest incidences of ovarian cancer in the world (around 15 cases per 100,000 women). We have conducted a review of the recent literature with focus on the Nordic countries, on genetic susceptibility to ovarian cancer, and the clinical implications in relation to the BRCA1 and BRCA2 genes. One of the strongest risk factors for ovarian cancer is a family history of ovarian and\/or early\u2010onset breast cancer. It is thought that germline mutations in BRCA1\/2 might be responsible for as much as 10% of all ovarian cancer cases and all families containing either multiple case, site\u2010specific ovarian cancer cases or breast and ovarian cancers together. Data from several international studies suggest that the lifetime risk of ovarian cancer in a BRCA1 mutation carrier can vary from 18 to 56% and from 14 to 27% in a BRCA2 carrier, depending on the presence\/absence of a family history of the disease. Genetic evaluation and testing is used in many countries to identify families with BRCA1\/2 mutations. Once a mutation has been identified, genetic counseling and testing can be offered to unaffected family members. Prophylactic oophorectomy in unaffected mutation carriers will eliminate the risk of ovarian cancer, although there is a slight residual risk of peritoneal cancer. During oophorectomy, the Fallopian tube should also be removed. If a woman does not want prophylactic oophorectomy, then tubal ligation or oral contraceptive use can be considered as these have been shown to reduce ovarian cancer risk also in mutation carriers.<\/jats:p>","DOI":"10.1080\/00016340500324621","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T17:35:11Z","timestamp":1260293711000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention"],"prefix":"10.1111","volume":"85","author":[{"given":"MARIE","family":"S\u00d8GAARD","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SUSANNE","family":"KR\u00dcGER KJ\u00c6R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SIMON","family":"GAYTHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,31]]},"reference":[{"issue":"2","key":"e_1_2_6_2_2","first-page":"566","article-title":"Genetic epidemiology of epithelial ovarian cancer","volume":"71","author":"Amos CI","year":"1993","journal-title":"Cancer"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb10148.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1966.03870080050009"},{"issue":"5","key":"e_1_2_6_5_2","first-page":"717","article-title":"Familial association of carcinoma of the breast and ovary","volume":"138","author":"Lynch HT","year":"1974","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7545954"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/378789a0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/301749"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/302583"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200652"},{"issue":"16","key":"e_1_2_6_11_2","first-page":"3663","article-title":"High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients","volume":"56","author":"Johannesdottir G","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00050-7"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00223-4"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.09.016"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.38.6.361"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704173361602"},{"issue":"10","key":"e_1_2_6_17_2","first-page":"2433","article-title":"Frequency of germline and somatic BRCA1 mutations in ovarian cancer","volume":"4","author":"Berchuck A","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00110-6"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6430"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11338"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)70476-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/318787"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/342506"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.10090"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.17.2260"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/302853"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450401"},{"issue":"12","key":"e_1_2_6_28_2","first-page":"3776","article-title":"Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"8","author":"Satagopan JM","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00152-5"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1480"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20162"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pgp.0000101083.35393.cd"},{"issue":"5","key":"e_1_2_6_33_2","first-page":"1059","article-title":"Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast\u2010ovarian cancer families","volume":"60","author":"Levy\u2010Lahad E","year":"1997","journal-title":"Am J Hum Genet"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1196-1179"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-9525(99)01930-7"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00075-2"},{"issue":"2","key":"e_1_2_6_38_2","first-page":"271","article-title":"Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study","volume":"58","author":"Neuhausen SL","year":"1996","journal-title":"Am J Hum Genet"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03300-5"},{"issue":"3","key":"e_1_2_6_40_2","first-page":"441","article-title":"Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden","volume":"58","author":"Johannsson O","year":"1996","journal-title":"Am J Hum Genet"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200529"},{"issue":"1","key":"e_1_2_6_42_2","first-page":"265","article-title":"Breast and ovarian cancer incidence in BRCA1\u2010mutation carriers. Breast Cancer Linkage Consortium","volume":"56","author":"Easton DF","year":"1995","journal-title":"Am J Hum Genet"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910640608"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/302530"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705153362001"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/375033"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.4572"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-200210000-00011"},{"issue":"2","key":"e_1_2_6_49_2","first-page":"417","article-title":"BRCA1\/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases","volume":"63","author":"Ramus SJ","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.6095"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611073351901"},{"issue":"4","key":"e_1_2_6_52_2","first-page":"868","article-title":"Survival in familial, BRCA1\u2010associated, and BRCA2\u2010associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group","volume":"59","author":"Pharoah PD","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.397"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001703-200202000-00004"},{"key":"e_1_2_6_55_2","unstructured":"The American College of Medical Genetics Policy Statement: Genetic susceptibility to breast and ovarian Cancer: Assessment Counseling and Testing Guidelines 1999.http:\/\/www.acmg.net(verified 10\/20\/04)."},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1626"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116427"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90026-X"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390702"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024932427503"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90806-5"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.14.1791"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04642-0"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1980"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012158"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601692"},{"issue":"14","key":"e_1_2_6_67_2","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","article-title":"Occult ovarian tumours in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy","volume":"18","author":"Lu KH","year":"2000","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200110000-00009"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020119"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.17.1475"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02347-3"},{"issue":"2","key":"e_1_2_6_72_2","first-page":"87","article-title":"Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction","volume":"46","author":"Swisher EM","year":"2001","journal-title":"J Reprod Med"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1053\/beog.2002.0297"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540360065034"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2002.01055.x"},{"issue":"6","key":"e_1_2_6_76_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.1995.03520300065039","article-title":"Ovarian cancer. Screening, treatment, and follow\u2010up. NIH Consensus Development Panel on Ovarian Cancer","volume":"273","author":"NIH consensus conference","year":"1995","journal-title":"JAMA"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F00016340500324621","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/00016340500324621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:38:53Z","timestamp":1697402333000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1080\/00016340500324621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1080\/00016340500324621"],"URL":"https:\/\/doi.org\/10.1080\/00016340500324621","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"2010-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}